麦克赫里
基因传递
视网膜
报告基因
内吞作用
转染
RPE65型
化学
遗传增强
细胞生物学
玻璃体内给药
信使核糖核酸
视网膜变性
视网膜
核酸
基因表达
生物
生物化学
计算生物学
药物输送
分子生物学
载体(分子生物学)
内体
体内
病毒载体
脂质代谢
体外
作者
Jinghua Yu,Zesen Ma,Haiyang Tong,Yuanyuan Li,Dongsheng Li,Qingjun Zhu,Huajian Shi,Li Zhou,Changlin Tian,Baoqing Li,ChuanDong Cheng,Pei Lv
标识
DOI:10.1021/acs.molpharmaceut.5c01760
摘要
Inherited retinal diseases (IRDs) are a group of genetically heterogeneous neurodegenerative disorders that cause progressive vision loss. Gene therapies based on adeno-associated virus vectors have achieved notable progress in IRDs, but their limited packaging capacity and potential long-term toxicity constrain broader applications. Lipid nanoparticles (LNPs) have been clinically validated as nonviral delivery vehicles for nucleic acid therapeutics. Previous ocular studies have primarily focused on strategies such as surface modification and polyethylene glycol lipid engineering, which have provided valuable insights. However, systematic exploration of core formulation parameters, such as lipid component ratios, has received comparatively limited attention. In this study, we applied a design of experiments strategy to construct and evaluate LNP libraries for ocular delivery. Systematic screening identified formulation B11, which produced 2.6-fold and 3.0-fold reporter gene expression in vivo following intravitreal administration compared with benchmark SM-102 and MC3 formulations. Mechanistic analyses revealed that LNP B11 is internalized predominantly through caveolae-mediated endocytosis and macropinocytosis. In vivo, LNP B11 mediated mRNA expression localized to the retinal pigment epithelium, as demonstrated by mCherry expression. Furthermore, Cre mRNA delivery using B11 formulation induced tdTomato activation in Ai14 reporter mice more effectively than standard SM-102 and MC3 formulations, indicating that B11 supports functional protein expression in retinal tissue. Together, these findings identify B11 as a promising optimized LNP formulation for retinal mRNA delivery, highlighting the critical role of systematic formulation optimization in advancing nucleic acid therapeutics for retinal diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI